Skip to content

A Phase I, Randomised, Open Label, Single Center, Single Oral Dose, Three Treatment, Three Period, Three Sequence, Change-over Bioequivalence Study of Paracetamol Orodispersible Tablet 500 mg (Haleon) to assess Bioequivalence with Alvedon 500 mg Film-Coated Tablet (Haleon, Sweden) and Panadol 500 mg Film-Coated Tablet (Haleon, Australia) in Healthy Adult Subjects Under Fasting Conditions

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514198-23-00
Acronym
300141
Enrollment
54
Registered
2024-12-10
Start date
2025-03-05
Completion date
2025-06-16
Last updated
2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers, therapeutic indication not studied

Interventions

None listed

Sponsors

Haleon CH SARL
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026